Sunday 18 October 2026
Export ENTA’s income statement to Excel — free account
Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
11.10
0.37
−3.23%
Follow ENTA
| Sep '16 | Sep '17 | Sep '18 | Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
23.14 | 51.15 | 22.61 | 25.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | 5 | 6 | 4 | 4 | 2 | 4 | 2 | 3 | 4 |
P/S ratio |
5.71 | 8.82 | 7.84 | 5.73 | 7.45 | 11.80 | 12.40 | 2.78 | 3.24 | 3.91 |
Altman Z-Score |
28.42 | 23.00 | 50.70 | 27.89 | 19.28 | 17.79 | 11.63 | 0.07 | (0.78) | (1.41) |
P/FCF ratio |
16.21 | 18.09 | 61.72 | 17.83 | 161.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
31.28 | 18.00 | 28.24 | 24.44 | 21.51 | 13.57 | 8.31 | 2.58 | (0.20) | (2.79) |
P/Operating CF |
(236.92) | 15.83 | 57.14 | 137.70 | (59.04) | (54.51) | (68.80) | (10.18) | (21.08) | (39.36) |
Beneish M-Score |
(3.08) | (3.24) | 0.85 | (2.39) | (3.58) | (1.24) | (3.36) | (3.50) | (2.90) | (4.29) |
P/B ratio |
1.87 | 3.01 | 4.11 | 2.54 | 2.00 | 2.87 | 3.33 | 1.01 | 1.70 | 3.95 |
Price to Tangible BV |
1.87 | 3.01 | 4.11 | 2.54 | 2.00 | 2.87 | 3.33 | 1.01 | 1.70 | 3.95 |
EV/Sales |
3.33 | 6.65 | 6.34 | 4.10 | 4.30 | 9.29 | 9.51 | (1.89) | (0.44) | 1.02 |
EV/EBITDA |
8.63 | 24.89 | 14.56 | 23.59 | 0.00 | 0.00 | 0.00 | 1.09 | 0.25 | 0.00 |
EV/Operating CF |
8.20 | 12.98 | 44.86 | 11.78 | 74.24 | (12.89) | (9.67) | 1.45 | 0.38 | (3.45) |
EV/FCF |
9.45 | 13.63 | 49.96 | 12.75 | 93.25 | (12.75) | (9.43) | 1.34 | 0.31 | (2.07) |
Quick Ratio |
28.26 | 11.17 | 23.46 | 17.10 | 17.52 | 8.43 | 10.00 | 6.52 | 5.00 | 4.03 |
Current Ratio |
29.43 | 11.33 | 23.74 | 17.77 | 18.08 | 8.82 | 10.45 | 6.73 | 5.21 | 4.21 |
Net Debt/EBITDA |
(6.18) | (8.15) | (3.43) | (9.40) | 10.26 | 2.34 | 2.08 | 2.69 | 2.06 | 2.35 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.33 | 0.34 | 0.56 | 0.45 | 0.25 | 0.21 | 0.21 | 0.19 | 0.16 | 0.20 |
Operating CF/Net income |
1.65 | 2.97 | 0.41 | 1.54 | (0.20) | 0.89 | 0.70 | 0.77 | 0.68 | 0.24 |
Capex/Depreciation |
(1.49) | (0.88) | (1.77) | 5.03 | (0.37) | (0.14) | (0.51) | 18.68 | (14.98) | (2.53) |
Interest Coverage |
17.78 | 9.72 | 18.20 | 4.17 | (6.43) | (54.22) | (78.73) | (26.65) | (11.12) | (11.11) |
| 8.56% | 6.20% | 20.70% | 10.83% | (7.88%) | (18.48%) | (33.79%) | (49.74%) | (67.17%) | (84.63%) | |
| 8.22% | 5.83% | 19.42% | 10.26% | (7.41%) | (17.08%) | (29.91%) | (31.95%) | (27.67%) | (24.91%) | |
ROIC |
32.21% | 19.72% | 64.99% | 18.04% | (37.75%) | (44.06%) | (107.35%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
9.33% | 7.88% | 19.30% | 11.89% | (8.59%) | (27.35%) | (42.27%) | (35.98%) | (42.20%) | (42.83%) |
Average Days of Receivables |
53.10 | 37.68 | 118.72 | 91.27 | 108.88 | 228.73 | 207.73 | 182.57 | 208.55 | 38.45 |
Research and Development Expense of Revenue |
45.84% | 55.88% | 45.91% | 69.31% | 111.66% | 179.36% | 190.95% | 206.46% | 194.39% | 163.40% |
Selling, General and Administrative Expense of Revenue |
19.22% | 20.18% | 11.34% | 12.79% | 22.34% | 33.52% | 52.79% | 66.77% | 85.53% | 67.25% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.60% | 12.71% | 7.67% | 9.37% | 15.98% | 21.62% | 31.30% | 35.62% | 39.62% | 28.42% |
Graham Net Nets |
0.44 | 0.23 | 0.22 | 0.32 | 0.45 | 0.24 | 0.24 | 0.81 | 0.24 | (0.05) |
Graham Number |
19.21 | 18.20 | 41.37 | 35.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.32% | 1.96% | 4.42% | 3.96% | (3.91%) | (6.88%) | (11.39%) | (60.72%) | (52.90%) | (32.00%) |
Free Cash Flow Yield |
6.17% | 5.53% | 1.62% | 5.61% | 0.62% | (6.17%) | (8.13%) | (51.01%) | (44.12%) | (12.60%) |
Revenue per Share |
4.66 | 5.39 | 10.73 | 10.48 | 6.14 | 4.81 | 4.18 | 3.78 | 3.20 | 3.06 |
Operating CF per Share |
1.89 | 2.76 | 1.52 | 3.65 | 0.36 | (3.47) | (4.11) | (4.92) | (3.72) | (0.90) |
Capex per Share |
(0.25) | (0.13) | (0.15) | (0.28) | (0.07) | (0.04) | (0.10) | (0.43) | (0.85) | (0.60) |
Free Cash Flow per Share |
1.64 | 2.63 | 1.36 | 3.37 | 0.28 | (3.51) | (4.22) | (5.35) | (4.57) | (1.51) |
Cash per Share |
11.10 | 11.73 | 16.03 | 17.12 | 19.39 | 12.10 | 12.10 | 17.64 | 11.76 | 8.85 |
Shareholders Equity per Share |
14.26 | 15.82 | 20.45 | 23.62 | 22.85 | 19.80 | 15.60 | 10.34 | 6.09 | 3.03 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.26 | 15.82 | 20.45 | 23.62 | 22.85 | 19.80 | 15.60 | 10.34 | 6.09 | 3.03 |
Free Cash Flow |
31.07 | 50.15 | 26.24 | 66.00 | 5.64 | (70.75) | (86.91) | (112.21) | (96.71) | (32.17) |
Working Capital |
224.27 | 216.84 | 364.36 | 379.24 | 412.68 | 282.85 | 281.89 | 360.00 | 242.32 | 155.78 |
Capital Expenditures |
(4.74) | (2.51) | (2.98) | (5.42) | (1.44) | (0.75) | (2.12) | (9.06) | (17.95) | (12.90) |
Net Current Asset Value |
220.82 | 212.86 | 359.84 | 374.51 | 406.29 | 279.66 | 257.64 | 177.25 | 52.01 | (11.68) |
EV/EBIT |
9.52 | 27.76 | 14.84 | 22.90 | 0.00 | 0.00 | 0.00 | 1.09 | 0.24 | 0.00 |
Capex to Sales |
0.05 | 0.02 | 0.01 | 0.03 | 0.01 | 0.01 | 0.02 | 0.11 | 0.27 | 0.20 |
Price to Operating Income |
16.33 | 36.85 | 18.34 | 32.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.40 | 0.35 | 0.20 | (0.10) | 0.46 | 0.92 | 0.67 | (0.04) | 0.04 | 0.14 |
Cash ROIC |
6.47% | 9.55% | 3.74% | 8.27% | 0.67% | (11.00%) | (15.23%) | (19.13%) | (25.61%) | (12.69%) |
Accounts Receivable Turnover |
6.18 | 8.77 | 5.31 | 3.46 | 2.79 | 1.99 | 1.57 | 1.79 | 1.73 | 2.87 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Average Receivables |
14.28 | 11.73 | 38.91 | 59.26 | 43.92 | 48.68 | 54.93 | 44.33 | 39.13 | 22.76 |
Average Payables |
2.46 | 3.55 | 4.23 | 5.72 | 6.21 | 7.64 | 7.77 | 5.05 | 6.05 | 4.98 |
Average Assets |
263.65 | 303.96 | 370.43 | 452.03 | 487.98 | 462.46 | 407.10 | 418.84 | 419.46 | 328.69 |
Average Common Equity |
253.05 | 285.81 | 347.68 | 428.09 | 459.04 | 427.50 | 360.38 | 269.03 | 172.77 | 96.77 |
Columns are period end dates